Previous close | 15.90 |
Open | 15.85 |
Bid | 0.00 x 12000 |
Ask | 0.00 x 12000 |
Day's range | 15.85 - 15.90 |
52-week range | 15.31 - 49.99 |
Volume | |
Avg. volume | 103 |
Market cap | 1.075B |
Beta (5Y monthly) | 0.80 |
PE ratio (TTM) | N/A |
EPS (TTM) | -9.91 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 22.80 |
SOMERVILLE, Mass., March 26, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported fourth quarter and annual financial results and business highlights for the year ended December 31, 2023, including recent commercial and operational progress.
SOMERVILLE, Mass., March 25, 2024--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss fourth quarter and 2023 annual results and business updates on March 26, 2024, at 8:00 a.m. ET.
SOMERVILLE, Mass., March 18, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it has entered into a $175 million five-year, term loan facility with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"). The transaction strengthens the Company’s balance sheet as it executes on the commercial launches for its three FDA approved gene therapies – LYFGENIA for sickle cell disease, ZYNTEGLO for beta-thalassemia and SKYSONA for cerebral adrenoleukodystrophy.